Vascular Basement Membrane Thickening in Diabetic Retinopathy

REFERENCES

• Wagener H. P. and Wilder R. M. The Retinitis of Diabetes Mellitus: Preliminary Report. J Am Med Assoc. 1921;76(6): p. 515–517.
   Google Scholar
• Ashton N. Vascular changes in diabetes with particular reference to the retinal vessels; preliminary report. Br J Ophthalmol. 1949;33(7): p. 407–20.
   Google Scholar
• Botting A.J., Brown A.L. and Divertie M.B.. The Pulmonary Lesion In A Patient With Goodpasture’s Syndrome, As Studied With The Electron Microscope. Am J Clin Pathol. 1964;42: p. 387–94.
   Google Scholar
• Kajikawa K and Kakihara. S. An electron microscope study of the basement membrane of proliferated bile ductules. Exp Mol Pathol. 1969;11(1): p. 17–27.
   Google Scholar
• Naccarato R., Maschio G., Sirigu F., et al. The muscle in diabetes mellitus. A histologic (light and electron microscope) and biochemical study by means of needle biopsy. Virchows Arch B Cell Pathol. 1970;4(4): p. 283–93.
   Google Scholar
• Kozak W.M., Marker N.A. and Elmer K.K. Effects of aldose reductase inhibition on the retina and health indices of streptozotocin-diabetic rats. Doc Ophthalmol. 1986;64(4): p. 355–77.
   Google Scholar
• Martinez-Hernandez A. and Amenta P.S. The basement membrane in pathology. Lab Invest. 1983;48(6): p. 656–77.
   Google Scholar
• Tang J., Mohr S., Du Y.D., et al. Non-uniform distribution of lesions and biochemical abnormalities within the retina of diabetic humans. Curr Eye Res. 2003;27(1): p. 7–13.
   Google Scholar
• Dische F.E, Anderson VE, Keane SJ, et al. Incidence of thin membrane nephropathy: morphometric investigation of a population sample. J Clin Pathol. 1990;43: p. 457–460
   PubMed Web of Science ®Google Scholar
• Haas M. Thin glomerular basement membrane nephropathy: Incidence in 3471 consecutive renal biopsies examined by electron microscopy. Arch Pathol Lab Med. 2006;130: p. 699–706.
   PubMed Web of Science ®Google Scholar
• Vick N.A. Skeletal muscle capillary basement membranes in humans. Acta Neuropathol. 1971;17(1): p. 1–5.
   Google Scholar
• Begieneman M.P., van de Goot F.R., Krijnen PA, et al. The basement membrane of intramyocardial capillaries is thickened in patients with acute myocardial infarction. J Vasc Res. 2009; 47: p. 54–60.
   Google Scholar
• Siperstein M.D., Unger R.H. and Madison L.L. Studies of muscle capillary basement membranes in normal subjects, diabetic, and prediabetic patients. J Clin Invest. 1968;47(9): p. 1973–99.
   Google Scholar
• Lindsay D.C., Anand I.S., Bennett J.G., et al. Ultrastructural analysis of skeletal muscle. Microvascular dimensions and basement membrane thickness in chronic heart failure. Eur Heart J. 1994;15(11): p. 1470–6.
   Google Scholar
• Quabbe H.J., Schenk K.E., Schneider H., et al. Absence of muscle capillary basement membrane thickening and retinopathy in patients with myocardial infarction and impaired i.v. glucose tolerance. Acta Diabetol Lat. 1983;20(4): p. 321–7.
   Google Scholar
• Kuiper E.J., van Zijderveld R., Roestenberg P., et al. Connective tissue growth factor is necessary for retinal capillary basal lamina thickening in diabetic mice. J Histochem Cytochem. 2008; 56: p. 785–792.
   PubMed Web of Science ®Google Scholar
• Carlson E.C., Audette J.L., Veitenheimer N.J., et al. Ultrastructural morphometry of capillary basement membrane thickness in normal and transgenic diabetic mice. Anat Rec A Discov Mol Cell Evol Biol. 2003;271(2): p. 332–41.
   Google Scholar
• Cherian S., Roy S., Pinheiro A., et al. Tight glycemic control regulates fibronectin expression and basement membrane thickening in retinal and glomerular capillaries of diabetic rats. Invest Ophthalmol Vis Sci.. 2009;50(2): p. 943–9.
   Google Scholar
• Dosso A.A., Rungger-Brandle E. and Leuenberger P.M. Ultrastructural alterations in capillaries of the diabetic hypertensive rat retina: protective effects of ACE inhibition. Diabetologia. 2004;47(7): p. 1196–201.
   Google Scholar
• Mansour S.Z., Hatchell D.L., Chandler D., et al. Reduction of basement membrane thickening in diabetic cat retina by sulindac. Invest Ophthalmol Vis Sci. 1990;31(3): p. 457–63.
   Google Scholar
• Hood J.C., Savige J., Seymour A.E., et al. Ultrastructural appearance of renal and other basement membranes in the Bull terrier model of autosomal dominant hereditary nephritis. Am J Kidney Dis. 2000;36(2): p. 378–91.
   Google Scholar
• Stitt A.W., Anderson H.R., Gardiner T.A., et al. Diabetic retinopathy: quantitative variation in capillary basement membrane thickening in arterial or venous environments. Br J Ophthalmol. 1994;78(2): p. 133–7.
   Google Scholar
• Ljubimov A.V., Burgeson R.E., Butkowski R.J., et al. Basement membrane abnormalities in human eyes with diabetic retinopathy. J Histochem Cytochem. 1996;44(12): p. 1469–79.
   Google Scholar
• Timpl R., Dziadek M., Fujiwara S., et al. Nidogen: a new, self-aggregating basement membrane protein. Eur J Biochem. 1983;137(3): p. 455–65.
   Google Scholar
• Charonis A.S. and Tsilibary. E.C., 1990. Assembly of Basement Membrane Protein, in Organization and Assembly of Plant and Animal Extracellular Matrix, Adair S.W. and Mecham R.P., , Editors. San Diego, CA: Academic Press, Inc. p. 85–117.
   Google Scholar
• Brazel D., Pollner R., Oberbaumer I., et al. Human basement membrane collagen (type IV). The amino acid sequence of the alpha 2(IV) chain and its comparison with the alpha 1(IV) chain reveals deletions in the alpha 1(IV) chain. Eur J Biochem. 1988;172(1): p. 35–42.
   Google Scholar
• Vuorio E, de Crombrugghe B. The family of collagen genes. Annu Rev Biochem.1990; 59: p. 837–872.
   PubMed Web of Science ®Google Scholar
• Hudson BG, Tryggvason K, Sundaramoorthy M, et al. Alport’s syndrome, Goodpasture’s syndrome, and type IV collagen. N Engl J Med. 2003; 348: p. 2543–2556.
   PubMed Web of Science ®Google Scholar
• Khoshnoodi J., Pedchenko V. and Hudson B.G. Mammalian collagen IV. Microsc Res Tech. 2008;71(5): p. 357–70.
   Google Scholar
• Risteli J., Bachinger H.P., Engel J., et al. 7-S collagen: characterization of an unusual basement membrane structure. Eur J Biochem. 1980;108(1): p. 239–50.
   Google Scholar
• Timpl R., Wiedemann H., van Delden V., et al. A network model for the organization of type IV collagen molecules in basement membranes. Eur J Biochem. 1981;120(2): p. 203–11.
   Google Scholar
• Timpl R, et al. Macromolecular organization of type IV collagen. In: New Trends in Basement Membrane Research. New York: Raven Press, 1982; p. 57.
   Google Scholar
• de Fougerolles A.R., Sprague A.G., Nickerson-Nutter C.L., et al. Regulation of inflammation by collagen-binding integrins alpha1beta1 and alpha2beta1 in models of hypersensitivity and arthritis. J Clin Invest. 2000;105(6): p. 721–9.
   Google Scholar
• Pankov R., and Yamada K.M. Fibronectin at a glance. J Cell Sci. 2002;115(Pt 20): p. 3861–3.
   PubMed Web of Science ®Google Scholar
• Geiger B., Bershadsky A., Pankov R., et al. Transmembrane crosstalk between the extracellular matrix–cytoskeleton crosstalk. Nat Rev Mol Cell Biol. 2001;2(11): p. 793–805.
   Google Scholar
• Mandarino LJ, Sundarraj N, Finlayson J, et al. Regulation of fibronectin and laminin synthesis by retinal capillary endothelial cells and pericytes in vitro. Exp Eye Res. 1993; 57: p. 609–621.
   Google Scholar
• Cagliero E, Maiello M, Boeri D, et al. Increased expression of basement membrane components in human endothelial cells cultured in high glucose. J Clin Invest. 1988; 82: p. 735–738.
   PubMed Web of Science ®Google Scholar
• Roy S, Cagliero E, Lorenzi M. Fibronectin overexpression in retinal microvessels of patients with diabetes. Invest Ophthalmol Vis Sci. 1996;37:258–266.
   PubMed Web of Science ®Google Scholar
• Foidart J.M., Bere, Jr., Yaar M.E.W., et al. Distribution and immunoelectron microscopic localization of laminin, a noncollagenous basement membrane glycoprotein. Lab Invest. 1980;42(3): p. 336–42.
   Google Scholar
• Madri J.A., Roll F.J., Furthmayr H., et al. Ultrastructural localization of fibronectin and laminin in the basement membranes of the murine kidney. J Cell Biol. 1980;86(2): p. 682–7.
   Google Scholar
• Laurie G.W., Leblond C.P. and Martin G.R. Localization of type IV collagen, laminin, heparan sulfate proteoglycan, and fibronectin to the basal lamina of basement membranes. J Cell Biol. 1982;95(1): p. 340–4.
   Google Scholar
• Engel J., Odermatt E., Engel A., et al. Shapes, domain organizations and flexibility of laminin and fibronectin, two multifunctional proteins of the extracellular matrix. J Mol Biol. 1981;150(1): p. 97–120.
   Google Scholar
• Marinkovich M.P. Tumour microenvironment: laminin 332 in squamous-cell carcinoma. Nat Rev Cancer. 2007;7(5): p. 370–80.
   Google Scholar
• Timpl R., Tisi D., Talts J.F., et al. Structure and function of laminin LG modules. Matrix Biol. 2000;19(4): p. 309–17.
   Google Scholar
• Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110(6): p. 673–87.
   PubMed Web of Science ®Google Scholar
• Sung U., O’Rear J.J. and Yurchenco P.D.. Localization of heparin binding activity in recombinant laminin G domain. Eur J Biochem. 1997;250(1): p. 138–43.
   Google Scholar
• Terranova V.P., Rohrbach D.H. and Martin. G.R. Role of laminin in the attachment of PAM 212 (epithelial) cells to basement membrane collagen. Cell. 1980;22(3): p. 719–26.
   Google Scholar
• Kumar V., Abbas A.B., Fausto N., et al. 2007. Robbins Basic Pathology, 8th Ed. Philadelphia, PA: Saunders.
   Google Scholar
• Ledbetter S.R., Fisher L.W. and Hassell. J.R. Domain structure of the basement membrane heparan sulfate proteoglycan. Biochemistry. 1987;26(4): p. 988–95.
   Google Scholar
• Paulsson M., Yurchenco P.D., Ruben G.C., et al. Structure of low density heparan sulfate proteoglycan isolated from a mouse tumor basement membrane. J Mol Biol. 1987;197(2): p. 297–313.
   Google Scholar
• Laurie G.W., Inoue S., Bing J.T., et al. Visualization of the large heparan sulfate proteoglycan from basement membrane. Am J Anat. 1988;181(3): p. 320–6.
   Google Scholar
• Hassell J.R., Leyshon W.C., Ledbetter S.R., et al. Isolation of two forms of basement membrane proteoglycans. J Biol Chem. 1985;260(13): p. 8098–105.
   Google Scholar
• Fransson L.A., Carlstedt I., Coster L., et al. The functions of the heparan sulphate proteoglycans. Ciba Found Symp. 1986;124: p. 125–42.
   Google Scholar
• Frisch S.M., and Ruoslahti. E. Integrins and anoikis. Curr Opin Cell Biol. 1997;9(5): p. 701–6.
   Google Scholar
• Brem R.B., Robbins S.G., Wilson D.J., et al. Immunolocalization of integrins in the human retina. Invest Ophthalmol Vis Sci. 1994;35(9): p. 3466–74.
   Google Scholar
• Heino J. The collagen receptor integrins have distinct ligand recognition and signaling functions. Matrix Biol. 2000;19:319–323.
   PubMed Web of Science ®Google Scholar
• Hemler M.E., Huang C., Schwarz L. The VLA protein family. Characterization of five distinct cell surface heterodimers each with a common 130,000 molecular weight beta subunit. J Biol Chem. 1987;262:3300–3309.
   PubMed Web of Science ®Google Scholar
• Hemler M.E., Crouse C., Takada Y, et al. Multiple very late antigen (VLA) heterodimers on platelets. Evidence for distinct VLA-2, VLA-5 (fibronectin receptor), and VLA-6 structures. J Biol Chem. 1988; 263: p. 7660–7665.
   PubMed Web of Science ®Google Scholar
• Chakrabarti S., Ma N. and Sima A.A. Anionic sites in diabetic basement membranes and their possible role in diffusion barrier abnormalities in the BB-rat. Diabetologia. 1991;34(5): p. 301–6.
   Google Scholar
• Beltramo E., Pomero F., Allione A., et al. Pericyte adhesion is impaired on extracellular matrix produced by endothelial cells in high hexose concentrations. Diabetologia. 2002; 45: p. 416–419.
   Google Scholar
• Beltramo E., Buttiglieri S., Pomero F., et al. A study of capillary pericyte viability on extracellular matrix produced by endothelial cells in high glucose. Diabetologia. 2003; 46: p. 409–415.
   Google Scholar
• Roy S., Sato T. Role of vascular basement membrane components in diabetic microangiopathy. Drug News Perspect. 2000;13(2): p. 91–8.
   Google Scholar
• Roy S., Sato T., Paryani G., et al. Downregulation of fibronectin overexpression reduces basement membrane thickening and vascular lesions in retinas of galactose-fed rats. Diabetes. 2003; 52: p. 1229–1234.
   PubMed Web of Science ®Google Scholar
• Roy S., Lorenzi M. Early biosynthetic changes in the diabetic-like retinopathy of galactose-fed rats. Diabetologia. 1996;39: p. 735–738.
   PubMed Web of Science ®Google Scholar
• Oshitari T., Polewski P., Chadda M., et al. Effect of combined antisense oligonucleotides against high-glucose- and diabetes-induced overexpression of extracellular matrix components and increased vascular permeability. Diabetes. 2006;55(1): p. 86–92.
   Google Scholar
• Chronopoulos A., Trudeau K., Roy S., et al. Altered Basement Membrane Composition and Increased Vascular Permeability in Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2009;50 (E-Abstract 26/A13).
   Google Scholar
• Chronopoulos A., Trackman P. and Roy S.. Effect of High Glucose on Lysyl Oxidase Expression in Rat Retinal Endothelial Cells. Diabetes. 2009;58(suppl 1): p. 866–P.
   Google Scholar
• Nishikawa T., Giardino I., Edelstein D., et al. Changes in diabetic retinal matrix protein mRNA levels in a common transgenic mouse strain. Curr Eye Res. 2000;21(1): p. 581–7.
   Google Scholar
• Davis G.E. and Senger D.R. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res. 2005;97(11): p. 1093–107.
   PubMed Web of Science ®Google Scholar
• Gerhardt H and Betsholtz. C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res. 2003;314(1): p. 15–23.
   Google Scholar
• Tucker B, Klassen H, Yang L, et al. Elevated MMP Expression in the MRL Mouse Retina Creates a Permissive Environment for Retinal Regeneration. Invest Ophthalmol Vis Sci. 2008; 49: 1686–1695.
   Google Scholar
• De Taeye B., Gils A., Declerck P.J. The story of the serpin plasminogen activator inhibitor 1: Is there any need for another mutant? Thromb Haemost. 2004;92:898–924.
   Google Scholar
• Das A., Boyd N., Jones T.R., et al. Inhibition of choroidal neovascularization by a peptide inhibitor of the urokinase plasminogen activator and receptor system in a mouse model. Arch Ophthalmol. 2004;122:1844–1849.
   PubMed Web of Science ®Google Scholar
• Zhang X., Cheng M., Chintala SK. Kainic acid-mediated upregulation of matrix metalloproteinase-9 promotes retinal degeneration. Invest Ophthalmol Vis Sci. 2004;45:2374–2383.
   PubMedGoogle Scholar
• Tsilibary E.C. Microvascular basement membranes in diabetes mellitus. J Pathol. 2003;200(4): p. 537–46.
   Google Scholar
• Giebel S.J., Menicucci G., McGuire P.G., et al. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest. 2005;85(5): p. 597–607.
   Google Scholar
• Xue M., Thompson P.J., Clifton-Bligh R., et al. Leukocyte matrix metalloproteinase-9 is elevated and contributes to lymphocyte activation in type I diabetes. Int J Biochem Cell Biol. 2005;37(11): p. 2406–16.
   Google Scholar
• Das A., McGuire P.G., Eriqat C., et al. Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci. 1999;40(3): p. 809–13.
   Google Scholar
• Yang R., Liu H., Williams I., et al. Matrix metalloproteinase-2 expression and apoptogenic activity in retinal pericytes: implications in diabetic retinopathy. Ann N Y Acad Sci. 2007;1103: p. 196–201.
   PubMed Web of Science ®Google Scholar
• Roy S, Maiello M, Lorenzi M. Increased expression of basement membrane collagen in human diabetic retinopathy. J Clin Invest. 1994;93:438–442.
   Google Scholar
• Robison W.G., Kador P.F. and Kinoshita. J.H. Retinal capillaries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor. Science. 1983;221(4616): p. 1177–9.
   Google Scholar
• Sorbinil Retinopathy Trial Research Group. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol. 1990;108:1234–1244.
   PubMed Web of Science ®Google Scholar
• Lorenzi M. The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient. Exp Diabetes Res. 2007;2007: p. 61038.
   PubMedGoogle Scholar
• Xia P., Kramer R.M. and King G.L. Identification of the mechanism for the inhibition of Na+,K(+)-adenosine triphosphatase by hyperglycemia involving activation of protein kinase C and cytosolic phospholipase A2. J Clin Invest. 1995;96(2): p. 733–40.
   Google Scholar
• Lee T.S., Saltsman K.A., Ohashi H., et al. Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications. Proc Natl Acad Sci U S A. 1989;86(13): p. 5141–5.
   Google Scholar
• Kreisberg J.I. Hyperglycemia and microangiopathy. Direct regulation by glucose of microvascular cells. Lab Invest. 1992;67(4): p. 416–26.
   Google Scholar
• Studer R.K., Craven P.A. and DeRubertis F.R. Role for protein kinase C in the mediation of increased fibronectin accumulation by mesangial cells grown in high-glucose medium. Diabetes. 1993;42(1): p. 118–26.
   Google Scholar
• Aiello L.P., Avery R.L., Arrigg P.G., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22): p. 1480–7.
   PubMedGoogle Scholar
• Katsura Y., Okano T., Noritake M., et al. Hepatocyte growth factor in vitreous fluid of patients with proliferative diabetic retinopathy and other retinal disorders. Diabetes Care. 1998;21(10): p. 1759–63.
   Google Scholar
• Pfeiffer A. and Schatz. H. Diabetic microvascular complications and growth factors. Exp Clin Endocrinol Diabetes. 1995;103(1): p. 7–14.
   Google Scholar
• Budhiraja S. and Singh. J. Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications. Fundam Clin Pharmacol. 2008;22(3): p. 231–40.
   Google Scholar
• Koya D., Jirousek M.R., Lin Y.W., et al. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest. 1997;100(1): p. 115–26.
   PubMedGoogle Scholar
• Eli Lilly A.C. (Pressrelease): Data Presented at ADA: Roboxistaurin mesylate may reduce moderate visual loss in people with moderate to severe diabetic retinopathy. 2003; June14,2003.
   Google Scholar
• Clarke M, Dodson PM. PKC inhibition and diabetic microvascular complications. BestPract Res Clin Endocrinol Metab. 2007;21:573–586.
   PubMed Web of Science ®Google Scholar
• Eli Lilly AC. Data presented at ADA: Roboxistaurin mesylate may reduce moderate visual loss in people with moderate to severe diabetic retinopathy. Press Release: June 14, 2003.
   Google Scholar
• Degenhardt T.P., Thorpe S.R. and Baynes J.W. Chemical modification of proteins by methylglyoxal. Cell Mol Biol (Noisy-le-grand). 1998;44(7): p. 1139–45.
   PubMed Web of Science ®Google Scholar
• Stitt A.W., Li Y.M., Gardiner T.A., et al. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol. 1997;150(2): p. 523–31.
   Google Scholar
• Bhatwadekar AD, Glenn JV, Li G, et al. Advanced glycation of fibronectin impairs vascular repair by endothelial progenitor cells: implications for vasodegeneration in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008; 49: 1232–1241.
   Google Scholar
• McDonald DM, Coleman G, Bhatwadekar A, et al. Advanced glycation of the Arg-Gly-Asp (RGD) tripeptide motif modulates retinal microvascular endothelial cell dysfunction. Mol Vis. 2009; 15: 1509–1520.
   Google Scholar
• Kalfa T.A., Gerritsen M.E., Carlson E.C., et al. Altered proliferation of retinal microvascular cells on glycated matrix. Invest Ophthalmol Vis Sci. 1995;36(12): p. 2358–67.
   Google Scholar
• Mott J.D., Khalifah R.G., Nagase H., et al. Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int. 1997;52(5): p. 1302–12.
   Google Scholar
• Doi T., Vlassara H., Kirstein M., et al. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci U S A. 1992;89(7): p. 2873–7.
   Google Scholar
• Kirstein M., Aston C., Hintz R., et al. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest. 1992;90(2): p. 439–46.
   PubMed Web of Science ®Google Scholar
• Skolnik E.Y., Yang Z., Makita Z., et al. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med. 1991;174(4): p. 931–9.
   Google Scholar
• Gardiner T.A., Anderson H.R. and Stitt A.W. Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes. J Pathol. 2003;201(2): p. 328–33.
   Google Scholar
• Stitt A., Gardiner T.A., Alderson N.L., et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes. 2002;51(9): p. 2826–32.
   Google Scholar
• Clements R.S., Robison W.G. and Cohen. M.P. Anti-glycated albumin therapy ameliorates early retinal microvascular pathology in db/db mice. J Diabetes Complications. 1998;12(1): p. 28–33.
   Google Scholar
• Bolton WK, Cattran DC, Williams ME, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol. 2004; 24: 32–40.
   PubMed Web of Science ®Google Scholar
• Gore-Hyer E., Pannu J., Smith E.A., et al. Selective stimulation of collagen synthesis in the presence of costimulatory insulin signaling by connective tissue growth factor in scleroderma fibroblasts. Arthritis Rheum. 2003;48(3): p. 798–806.
   Google Scholar
• Paradis V., Perlemuter G., Bonvoust F., et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001;34(4 Pt 1): p. 738–44.
   Google Scholar
• Twigg S.M., Chen M.M., Joly A.H., et al. Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology. 2001;142(5): p. 1760–9.
   Google Scholar
• Twigg S.M., Joly A.H., Chen M.M., et al. Connective tissue growth factor/IGF-binding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation end-products in human dermal fibroblasts. Endocrinology. 2002;143(4): p. 1260–9.
   Google Scholar
• Zhou G., Li C. and Cai L. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway. Am J Pathol. 2004;165(6): p. 2033–43.
   Google Scholar
• Kuiper E.J., Hughes J.M., Van Geest R.J., et al. Effect of VEGF-A on expression of profibrotic growth factor and extracellular matrix genes in the retina. Invest Ophthalmol Vis Sci. 2007;48(9): p. 4267–76.
   Google Scholar
• Qi W., Chen X., Twigg S., et al. Tranilast attenuates connective tissue growth factor-induced extracellular matrix accumulation in renal cells. Kidney Int. 2006;69(6): p. 989–95.
   Google Scholar
• Sohn M., Tan Y., Wang B., et al. Mechanisms of low-density lipoprotein-induced expression of connective tissue growth factor in human aortic endothelial cells. Am J Physiol Heart Circ Physiol. 2006;290(4): p. H1624–34.
   Google Scholar
• Otani A, Takagi H, Oh H, et al. Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes. Invest Ophthalmol Vis Sci. 2000; 41: 1192–1199.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Chen H, Xu X, et al. Effects of angiotensin-converting enzyme inhibitors and beta-adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathy. Exp Eye Res. 2007; 84: 745–752.
   PubMed Web of Science ®Google Scholar
• Gardiner T.A., Anderson H.R., Degenhardt T., et al. Prevention of retinal capillary basement membrane thickening in diabetic dogs by a non-steroidal anti-inflammatory drug. Diabetologia. 2003;46(9): p. 1269–75.
   Google Scholar
• Evans T., Deng D.X., Chen S., et al. Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats. Diabetes. 2000;49(4): p. 662–6.
   Google Scholar
• Deng D, Evans T, Mukherjee K, et al. Diabetes-induced vascular dysfunction in the retina: role of endothelins. Diabetologia. 1999; 42: 1228–1234.
   PubMed Web of Science ®Google Scholar
• Roy S. and Roth. T. Proliferative effect of high glucose is modulated by antisense oligonucleotides against fibronectin in rat endothelial cells. Diabetologia. 1997;40(9): p. 1011–7.
   Google Scholar
• Roy S., Zhang K., Roth T., et al. Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides. Nat Biotechnol. 1999;17(5): p. 476–9.
   Google Scholar
• Smith M.R., Xie T., Zhou Z.Z., et al. Efficacy of treatment with antisense oligonucleotides complementary to immunoglobulin sequences of bcl-2/immunoglobulin fusion transcript in a t(14;18) human lymphoma-scid mouse model. Clin Cancer Res. 2001;7(2): p. 400–6.
   Google Scholar
• Leung S., Miyake H., Zellweger T., et al. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int J Cancer. 2001;91(6): p. 846–50.
   Google Scholar
• Miyake H., Monia B.P. and Gleave. M.E. Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model. Int J Cancer. 2000;86(6): p. 855–62.
   Google Scholar
• Oshitari T., Brown D., and Roy S. SiRNA strategy against overexpression of extracellular matrix in diabetic retinopathy. Exp Eye Res. 2005;81(1): p. 32–7.
   Google Scholar
• Kagami S., Border W.A., Miller D.E., et al. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest. 1994;93(6): p. 2431–7.
   Google Scholar
• Ray P.E., Bruggeman L.A., Horikoshi S., et al. Angiotensin II stimulates human fetal mesangial cell proliferation and fibronectin biosynthesis by binding to AT1 receptors. Kidney Int. 1994;45(1): p. 177–84.
   Google Scholar
• Singh R., Alavi N., Singh A.K., et al. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes. 1999;48(10): p. 2066–73.
   Google Scholar
• Wolf G., Haberstroh U. and Neilson. E.G. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol. 1992;140(1): p. 95–107.
   Google Scholar
• Ziyadeh F.N., Sharma K., Ericksen M., et al. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest. 1994;93(2): p. 536–42.
   Google Scholar
• Sugiyama T, Okuno T, Fukuhara M, et al. Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes. Exp Eye Res. 2007;85:406–512.
   PubMed Web of Science ®Google Scholar
• Frank RN, et al., Keirn RJ, Kennedy A, et al. Galactose-induced retinal capillary basement membrane thickening: Prevention by Sorbinil. Invest Ophthalmol Vis Sci. 1983;24:1519–1524.
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Sima AA. Effect of aldose reductase inhibition and insulin treatment on retinal capillary basement membrane thickening in BB rats. Diabetes. 1989;38: 1181–1186.
   PubMed Web of Science ®Google Scholar
• McCaleb ML, McKean ML, Hohman TC, et al. Intervention with the aldose reductase inhibitor, tolrestat, in renal and retinal lesions of streptozotocin- diabetic rats. Diabetologia. 1991;34:695–701.
   Google Scholar
• Robison WG, Jr., Kador PF, Akagi Y, et al. Prevention of basement membrane thickening in retinal capillaries by a novel inhibitor of aldose reductase, tolrestat. Diabetes. 1986;35:295–299.
   PubMedGoogle Scholar